GlassScriptPhysician profile
Robert Kopec
NPI 1053746867
$3,455.68
in general payments reported to CMS, 2019-2025
18 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2022: $390 · 2023: $391 · 2024: $943 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,877 · Education: $15.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,877.03 |
| Education | $15.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,197.23 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $568.83 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $235.60 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $231.42 | 2022-2025 | Auvelity |
| Alkermes, INC. | $211.91 | 2021-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $179.92 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $173.70 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $167.70 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $109.56 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $88.74 | 2021-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $66.37 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $59.51 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $50.04 | 2025 | Trintellix |
| Corium, LLC | $36.34 | 2024 | Azstarys |
| Neurocrine Biosciences, INC. | $33.93 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $18.23 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.39 | 2021 | |
| Sumitomo Pharma America, INC. | $10.26 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kopec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.